Georgia's Online Cancer Information Center

Melanoma Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Melanoma
Cancer Type = Melanoma
There are currently 29 active Melanoma clinical trials in Georgia.
1.
A Beta-only IL-2 ImmunoTherapY Study
Cancer Type
Bile Duct Cancer, Bladder Cancer, Cervical Cancer, Colon/Rectal Cancer, Gallbladder Cancer, Melanoma, Ovarian Cancer, Sarcoma, Stomach/ Gastric Cancer
NCT ID
NCT05086692
Protocol IDs
MDNA11-01
NCI-2022-02678
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
2.
A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
Cancer Type
Melanoma, Unknown Primary
NCT ID
NCT05933577
Protocol IDs
V940-001
NCI-2023-05647
2023-503652-27-00
V940-001
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
3.
A Multi-site, Prospective, Observational Study in US Patients with Advanced Melanoma
Cancer Type
Melanoma
NCT ID
Protocol IDs
CA184-199
IMPULSE
BMS CA184-199
5.
NCORP Trial
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients with Advanced Melanoma
Cancer Type
Melanoma, Unknown Primary
NCT ID
NCT02339571
Protocol IDs
EA6141
NCI-2014-02674
Treatment Sites (5)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
6.
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
Cancer Type
Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Melanoma
NCT ID
NCT05091346
Protocol IDs
E7386-G000-201
NCI-2022-02226
2021-001568-10
KEYNOTE-C83
7.
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Cancer Type
Colon/Rectal Cancer, Lung Cancer, Melanoma
NCT ID
NCT02817633
Protocol IDs
4020-01-001
NCI-2016-01254
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
9.
Collecting Blood Samples from Patients with and without Cancer to Evaluate Tests for Early Cancer Detection
Cancer Type
Breast Cancer, Head and Neck Cancer, Hematopoietic Malignancies, Kidney Cancer, Leukemia, Melanoma, Sarcoma, Solid Tumor, Thyroid Cancer, Unknown Primary
NCT ID
NCT05334069
Protocol IDs
A212102
A212102
A212102
NCI-2022-02477
Treatment Sites (1)
10.
Dose Escalation Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
Cancer Type
Melanoma
NCT ID
NCT05479812
Protocol IDs
WTX-124x2101
NCI-2022-08451
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
11.
Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Melanoma, Ovarian Cancer, Unknown Primary
NCT ID
NCT05118841
Protocol IDs
ZX-4081
NCI-2022-02249
12.
Duvelisib in Combination with Nivolumab for Treatment of Unresectable Stage IIIB-IV Melanoma
Cancer Type
Melanoma
NCT ID
NCT04688658
Protocol IDs
HCC 20-155
NCI-2021-13070
13.
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C Melanoma Patients
Cancer Type
Melanoma
NCT ID
NCT03567889
Protocol IDs
PH-L19IL2TNF-01/18
NCI-2018-01862
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
14.
KZR-261 in Subjects With Advanced Solid Malignancies
Cancer Type
Colon/Rectal Cancer, Eye Cancer, Melanoma, Prostate Cancer , Solid Tumor, Unknown Primary
NCT ID
NCT05047536
Protocol IDs
KZR-261-101
NCI-2022-01096
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
15.
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
Cancer Type
Melanoma
NCT ID
NCT03860883
Protocol IDs
02.18
NCI-2019-07264
ANZMTG 02.18
Treatment Sites (1)
St. Joseph's /Candler Health System, INC
Savannah
Stephanie J. Reyes
912-819-5723
16.
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
Cancer Type
Hematopoietic Malignancies, Melanoma
NCT ID
NCT03589339
Protocol IDs
1100
NCI-2019-03108
NBTXR3-1100
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
17.
Perflutren Lipid Microspheres Ultrasound in Diagnosing Patients with Intraocular Tumors Undergoing Diagnostic Surgery
Cancer Type
Eye Cancer, Melanoma
NCT ID
NCT01930968
Protocol IDs
IRB0003943
Treatment Sites (1)
18.
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
Cancer Type
Colon/Rectal Cancer, Melanoma, Ovarian Cancer
NCT ID
NCT05585034
Protocol IDs
XmAb808-01
NCI-2023-00610
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
19.
Phase 1a/1b Study of STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Solid Tumors
Cancer Type
Brain & Spinal Cord Tumor, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Solid Tumor, Unknown Primary
NCT ID
NCT05098132
Protocol IDs
STK-012-101
NCI-2022-00633
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
21.
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Head and Neck Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Melanoma, Ovarian Cancer, Pancreatic Cancer, Sarcoma, Stomach/ Gastric Cancer
NCT ID
NCT04140526
Protocol IDs
ONC-392-001
R44CA250824-01
NCI-2020-06149
20193108
4R44CA250824-02
23.
Stereotactic Radiosurgery and Immune Checkpoint Inhibitors with NovoTTF-200M for the Treatment of Melanoma Brain Metastases
Cancer Type
Melanoma
NCT ID
NCT05341349
Protocol IDs
RAD5236-21
NCI-2021-05980
STUDY00003588
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
24.
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
Cancer Type
Lung Cancer, Melanoma
NCT ID
NCT03809624
Protocol IDs
Ph 1 INBRX-105
NCI-2019-02844
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
25.
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Cancer Type
Lung Cancer, Melanoma, Stomach/ Gastric Cancer
NCT ID
NCT04198766
Protocol IDs
Ph 1 INBRX-106
NCI-2020-06313
MK3475 KEYNOTE A99
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
26.
Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor
Cancer Type
Cervical Cancer, Head and Neck Cancer, Liver Cancer / Hepatoblastoma, Melanoma, Sarcoma, Skin Cancer (Non-Melanoma), Solid Tumor, Unknown Primary
NCT ID
NCT05103345
Protocol IDs
SGN-P01-002
NCI-2023-06281
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
27.
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Cancer Type
Brain Tumor, Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Melanoma, Neuroblastoma, Non-Hodgkin Lymphoma, Ovarian Cancer, Sarcoma, Uterine Cancer, Wilms Tumor
NCT ID
NCT04851119
Protocol IDs
PEPN2011
PEPN2011
NCI-2021-02852
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.